endometriosis
Women's health · 2024–2024
3decisions
2medicines
3carried consumer input
12individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dienogest Treatment of endometriosis, a chronic hormone-dependent gynaecological condition characterised by dysmenorrhea, pelvic pain, and dyspareunia. | Jul 2024 | Recommended with restriction | input received |
| relugolix with estradiol and norethisterone acetate Symptomatic treatment of moderate to severe pain associated with endometriosis in women of reproductive age (18 years and older) who have experienced… | Mar 2024 | Recommended with restriction | 3 individuals Pelvic Pain Foundation |
| relugolix with estradiol and norethisterone acetate Treatment of moderate to severe pain associated with endometriosis in women who have failed to gain adequate pain relief from hormonal treatments and… | Nov 2024 | Recommended with restriction | 9 individuals Research Institute |
Who spoke
Pelvic Pain Foundation · Research Institute
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.